• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188894 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
! x' x' ~3 n, j& H; A7 X
/ P8 {" |, W# P
/ d. X4 z+ O+ vSub-category:
0 e- U( ]+ Y0 ?/ ]Molecular Targets
) d& v4 u- m' C  ^% s4 m! Q7 s
6 U8 G0 O8 d, ~, U
/ B: w# F0 x) U4 ]+ x( ^6 r" z+ C( B2 d2 sCategory:
0 p) p) b4 H4 ~$ b+ _Tumor Biology ! i+ U5 {: `0 n
" ?4 g: Z, |6 u4 \- Z
! }& l& q2 Y  E, X- s1 y
Meeting:1 u) W' |4 c/ u7 t
2011 ASCO Annual Meeting & Y% z- d$ ?- Q! k2 @6 z8 c, H/ R

2 x( D; k$ V" h3 ^$ {1 I0 j, d& m( P) P( N& z8 }/ c  [
Session Type and Session Title:
% K! y0 o1 X; ?/ s$ s1 }: g2 c% gPoster Discussion Session, Tumor Biology
$ V7 A: g# b8 s, S; t# P9 j" Z& |3 c
0 g5 W' O7 b! H6 T! b' y7 @" p6 x
Abstract No:8 }5 {4 m+ F1 m2 i$ z# O
10517 . h) B* ?! g9 s8 [( U

  w* |; @6 V7 e, I# k
- R# g, ^# y% R% W2 z+ d4 F3 dCitation:' N, y) {0 y/ I/ D% t+ t' V1 z
J Clin Oncol 29: 2011 (suppl; abstr 10517)
& L% M0 a8 R. U7 [  U5 G/ ~) J2 B6 T1 f9 B& n9 a  E* U' U+ R, k

! |# h2 \( J2 n6 O; YAuthor(s):
6 \0 m( D6 Q- jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
0 \& \0 k5 R  _' V. g
7 _% q: ?: n+ g+ I: s4 D5 Z8 A) T  |/ I) \* u

3 a6 d& }' T' d9 H$ AAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! [2 u. h4 k% @' v
, k, ~0 Y! K/ d' K* ]
Abstract Disclosures1 R- N; R! H) H2 ~3 S

1 r3 ^% B- [- d, T) OAbstract:
, V, W1 B1 Y9 {3 J" S
8 o! F$ |3 R  X2 m6 R: c% {" d/ x0 U/ N
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- T9 h; l3 k7 f: j7 j. O9 u

1 [4 A- l3 d  d; s1 ]' M  C
1 t. m9 U$ `7 e# k9 a6 @
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ' [$ J4 j1 i& w4 q: a' o$ r6 e
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

1 Y/ }+ B% C9 ?# A& x化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 . Z7 i! J* c7 M0 k% l
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。. L6 ~3 }4 }' {% ]
ALK一个指标医院要900多 ...

* @; O* x- h* e5 V平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
1 i9 x6 A) Y( J4 E0 }% S# N
. ^1 m- T1 p9 L现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表